Literature DB >> 18174745

The epidemiology and management of pituitary incidentalomas.

Adrian F Daly1, Maria Cristina Burlacu, Elena Livadariu, Albert Beckers.   

Abstract

PREVALENCE: The prevalence of pituitary tumors has been a topic of controversy for many years. Autopsy and radiological series show that pituitary incidentalomas may be present in one of six people. Recent epidemiological data suggest that clinically apparent pituitary adenomas have a prevalence of approximately one in 1,000 people in the general population. The disconnect between these two prevalence rates underlines the common clinical quandary of how to manage pituitary incidentalomas, particularly those lacking clinical signs/symptoms or hormonal abnormalities. MANAGEMENT: The natural history of incidentalomas suggests that periodic hormonal, clinical and radiological follow-up is the optimal approach. In the absence of tumor growth or relevant symptoms, screening can be continued intermittently or curtailed based on the clinical judgment of the physician. In the presence of hormonal hypersecretion, the management of pituitary incidentalomas, whether they are micro- or macroadenomas, should follow accepted clinical guidelines. For incidental pituitary macroadenomas without hormonal hypersecretion, clinical management should also include assessments for visual field impairment or hypopituitarism. In such cases, regular radiological and hormonal follow-up is required to identify tumor growth or the appearance of new symptoms. In the presence of tumor growth or new hormonal abnormalities, surgical options should be considered and discussed with the patient. Copyright (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2007        PMID: 18174745     DOI: 10.1159/000110624

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  11 in total

Review 1.  The rational use of pituitary stimulation tests.

Authors:  Stephan Petersenn; Hans-Jürgen Quabbe; Christof Schöfl; Günter K Stalla; Klaus von Werder; Michael Buchfelder
Journal:  Dtsch Arztebl Int       Date:  2010-06-25       Impact factor: 5.594

Review 2.  MicroRNAs in the human pituitary.

Authors:  Milani Sivapragasam; Fabio Rotondo; Ricardo V Lloyd; Bernd W Scheithauer; Michael Cusimano; Luis V Syro; Kalman Kovacs
Journal:  Endocr Pathol       Date:  2011-09       Impact factor: 3.943

3.  Specific inhibition of mTOR pathway induces anti-proliferative effect and decreases the hormone secretion in cultured pituitary adenoma cells.

Authors:  Rong Xie; Wen-Qiang He; Ming Shen; Xue-Fei Shou; Yong-Fei Wang; Wei-Min Bao; Yao Zhao
Journal:  J Neurooncol       Date:  2015-08-22       Impact factor: 4.130

Review 4.  Pituitary incidentalomas.

Authors:  George A Scangas; Edward R Laws
Journal:  Pituitary       Date:  2014-10       Impact factor: 4.107

5.  Pituitary incidentalomas: analysis of a neuroradiological cohort.

Authors:  César Esteves; Celestino Neves; Luís Augusto; Joana Menezes; Josué Pereira; Irene Bernardes; José Fonseca; Davide Carvalho
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

6.  MicroRNA profile indicates downregulation of the TGFβ pathway in sporadic non-functioning pituitary adenomas.

Authors:  Henriett Butz; István Likó; Sándor Czirják; Péter Igaz; Márta Korbonits; Károly Rácz; Attila Patócs
Journal:  Pituitary       Date:  2011-06       Impact factor: 4.107

7.  Clinicopathologic analysis of pituitary adenoma: a single institute experience.

Authors:  Hwa Jin Cho; Hanna Kim; Yoon Jin Kwak; Jeong Wook Seo; Sun Ha Paek; Chul-Ho Sohn; Jung Min Yun; Da Seu Ran Kim; Peter Kang; Peom Park; Sung-Hye Park
Journal:  J Korean Med Sci       Date:  2014-02-27       Impact factor: 2.153

8.  Expression and Clinical Significance of miR-26a and Pleomorphic Adenoma Gene 1 (PLAG1) in Invasive Pituitary Adenoma.

Authors:  ChuanTing Yu; JiXia Li; FengNan Sun; JinPeng Cui; HuaLi Fang; GuoLang Sui
Journal:  Med Sci Monit       Date:  2016-12-24

9.  Pituitary incidentalomas detected with technetium-99m MIBI in patients with suspected parathyroid adenoma: preliminary results.

Authors:  Ekaterina Tiktinsky; Tifha Horne; Michael Friger; Svetlana Agranovich; Sophie Lantsberg
Journal:  World J Nucl Med       Date:  2012-01

10.  Lycopene and beta-carotene induce growth inhibition and proapoptotic effects on ACTH-secreting pituitary adenoma cells.

Authors:  Natália F Haddad; Anderson J Teodoro; Felipe Leite de Oliveira; Nathália Soares; Rômulo Medina de Mattos; Fábio Hecht; Rômulo Sperduto Dezonne; Leandro Vairo; Regina Coeli Dos Santos Goldenberg; Flávia Carvalho Alcântara Gomes; Denise Pires de Carvalho; Mônica R Gadelha; Luiz Eurico Nasciutti; Leandro Miranda-Alves
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.